

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

12th November, 2021

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Dear Sirs,


Sub: Outcome of Board Meeting held on 12th November, 2021.

In continuation of our letter dated 02nd November, 2021 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2021, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 12th November, 2021. The meeting of the Board of Directors of the Company commenced at 10.00 A.M and concluded at 12.30 P.M.

A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed herewith.

Kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**


Manish Narang
President - Legal, Company Secretary & Compliance Officer
Encl.: a/a

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of Alkem Laboratories Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alkem Laboratories Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 September 2021 and year to date results for the period from 1 April 2021 to 30 September 2021 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

BSR & Co. LLP**Limited review report on unaudited quarterly consolidated financial results of Alkem Laboratories Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)****Alkem Laboratories Limited**

4. The Statement includes the results of the following entities:

Sr. No.	Name of entity	Relationship
1.	S & B Holdings B.V., Netherlands (S&B Holdings)	Wholly Owned Subsidiary
2.	ThePharmaNetwork, LLC, USA (TPN)	Wholly Owned Subsidiary of S&B Holdings
3.	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
4.	S & B Pharma LLC (w.e.f. 8 April 2020)	Wholly Owned Subsidiary of TPN
5.	S & B Pharma Inc., USA	Wholly Owned Subsidiary
6.	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7.	Ascend Laboratories (PTY) Ltd, South Africa (formerly known as Alkem Laboratories (PTY) Ltd)	Wholly Owned Subsidiary
8.	Enzene Biosciences Ltd, India	Subsidiary
9.	Cachet Pharmaceuticals Pvt Ltd, India	Subsidiary
10.	Indchemie Health Specialities Pvt Ltd, India	Subsidiary
11.	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
12.	Ascend GmbH, Germany	Wholly Owned Subsidiary
13.	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
14.	Ascend Laboratories SpA, Chile (Ascend Chile)	Wholly Owned Subsidiary
15.	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
16.	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
17.	Pharmacor Ltd., Kenya	Wholly Owned Subsidiary
18.	The Pharma Network, LLP, Kazakhstan	Wholly Owned Subsidiary
19.	Ascend Laboratories (UK) Ltd., UK	Wholly Owned Subsidiary
20.	Ascend Laboratories Ltd., Canada	Wholly Owned Subsidiary
21.	Alkem Foundation, India	Wholly Owned Subsidiary
22.	Connect 2 Clinic Private Limited (w.e.f. 12 June 2020), India	Wholly Owned Subsidiary
23.	Ascend Laboratories S.A.S, Colombia	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Limited review report on unaudited quarterly consolidated financial results of Alkem Laboratories Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Alkem Laboratories Limited

6. We did not review the interim financial results of 6 subsidiaries included in the Statement, whose interim financial results reflect total assets (before consolidation adjustment) of Rs. 17,307 million as at 30 September 2021 and total revenues (before consolidation adjustment) of Rs 4,579 million and Rs. 8,823 million, total net profit after tax (before consolidation adjustment) of Rs 79 million and Rs. 280 million and total comprehensive income (before consolidation adjustment) of Rs 34 million and Rs. 273 million, for the quarter ended 30 September 2021 and for the period from 1 April 2021 to 30 September 2021 respectively, and cash flows (net) of Rs. 934 million for the period from 1 April 2021 to 30 September 2021, as considered in the consolidated unaudited financial results. The interim financial results have been reviewed by other auditors whose reports have been furnished to us.

The interim financial results of 4 of the above subsidiaries are located outside India whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the interim financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's management.

Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these 6 subsidiaries is based solely on the reports of the other auditors and the conversion adjustments prepared by the management of the Company and reviewed by us and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

7. The Statement includes the interim financial information of 13 subsidiaries which have not been reviewed, whose interim financial information reflects total assets (before consolidation adjustment) of 4,256 million as at 30 September 2021 and total revenue (before consolidation adjustment) of Rs. 527 million and Rs. 802 million, total net loss after tax (before consolidation adjustment) of Rs. 21 million and Rs. 20 million and total comprehensive loss (before consolidation adjustment) of Rs. 2 million and Rs. 31 million for the quarter ended 30 September 2021 and for the period from 1 April 2021 to 30 September 2021 respectively, and cash flows (net) of Rs. 21 million for the period 1 April 2021 to 30 September 2021, as considered in the statement. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **BSR & Co. LLP**

Chartered Accountants

Firm's Registration No: 101248W/W-100022

BALAJIRAO
VENKATESWAR
RAO POTHANA

Digitally signed by BALAJIRAO
VENKATESWARAO POTHANA
Date: 2021.11.12 12:16:22
+05'30'

Balajirao Pothana

Partner

Membership No: 122632

UDIN No: 21122632AAAACZ5233

Mumbai

Date: 12 November 2021

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Unaudited Statement of Consolidated Financial Results for the Quarter and Six months ended 30 September 2021

(₹ in Million except per share data)

Particulars	Quarter ended			Six months ended		Year ended
	30.09.2021 Unaudited	30.06.2021 Unaudited	30.09.2020 Unaudited	30.09.2021 Unaudited	30.09.2020 Unaudited	31.03.2021 Audited
1 Income						
(a) Revenue from Operations	27,999.9	27,313.6	23,628.0	55,313.5	43,548.0	88,650.1
(b) Other Income	419.6	466.5	355.4	886.1	905.3	2,332.1
Total Income	28,419.5	27,780.1	23,983.4	56,199.6	44,453.3	90,982.2
2 Expenses						
(a) Cost of materials consumed	7,731.6	7,708.2	4,736.9	15,439.8	10,123.6	23,945.4
(b) Purchases of stock-in-trade	4,560.9	3,527.4	3,680.8	8,088.3	7,149.0	14,377.6
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,717.8)	(287.7)	921.7	(2,005.5)	(594.6)	(3,338.4)
(d) Employee benefits expense	4,944.9	5,318.3	4,080.1	10,263.2	8,022.4	16,210.3
(e) Finance costs	119.7	128.6	180.4	248.3	351.4	589.2
(f) Depreciation and amortisation expense	728.3	705.3	702.4	1,433.6	1,370.7	2,745.8
(g) Other expenses	6,236.5	5,118.8	4,203.6	11,355.3	7,625.8	18,031.3
Total Expenses	22,604.1	22,218.9	18,505.9	44,823.0	34,048.3	72,561.2
3 Profit before exceptional items and tax (1) - (2)	5,815.4	5,561.2	5,477.5	11,376.6	10,405.0	18,421.0
4 Exceptional items	-	-	-	-	-	-
5 Profit before tax (3) + (4)	5,815.4	5,561.2	5,477.5	11,376.6	10,405.0	18,421.0
6 Tax expense / (credit)						
(a) Current tax	1,082.6	1,181.9	1,141.9	2,264.5	2,142.5	3,965.3
(b) Deferred tax	(852.5)	(423.0)	(479.5)	(1,275.5)	(784.5)	(1,722.0)
Total Tax Expense (a + b)	230.1	758.9	662.4	989.0	1,358.0	2,243.3
7 Profit for the period (5) - (6)	5,585.3	4,802.3	4,815.1	10,387.6	9,047.0	16,177.7
8 Other Comprehensive Income (net of tax)						
(a) (i) Items that will not be reclassified to profit or loss	(36.8)	(21.5)	6.9	(58.3)	(5.7)	(89.2)
(ii) Income tax relating to items that will not be reclassified to profit or loss	13.1	8.9	(2.1)	22.0	2.1	29.9
(b) (i) Items that will be reclassified to profit or loss	58.7	15.5	(241.1)	74.2	(218.6)	(283.7)
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total other Comprehensive Income (net of tax)	35.0	2.9	(236.3)	37.9	(222.2)	(343.0)
9 Total Comprehensive Income for the period (7) + (8)	5,620.3	4,805.2	4,578.8	10,425.5	8,824.8	15,834.7
10 Profit attributable to						
a) Owners of the Company	5,442.6	4,681.2	4,720.6	10,123.8	8,940.7	15,850.2
b) Non-Controlling Interest	142.7	121.1	94.5	263.8	106.3	327.5
11 Other Comprehensive Income attributable to						
a) Owners of the Company	41.9	3.9	(237.8)	45.8	(222.8)	(339.6)
b) Non-Controlling Interest	(6.9)	(1.0)	1.5	(7.9)	0.6	(3.4)
12 Total Comprehensive Income attributable to						
a) Owners of the Company	5,484.5	4,685.1	4,482.8	10,169.6	8,717.9	15,510.6
b) Non-Controlling Interest	135.8	120.1	96.0	255.9	106.9	324.1
13 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1	239.1	239.1
14 Other Equity						73,528.2
15 Earnings Per Share (not annualised for the periods)						
(a) Basic (₹)	45.52	39.15	39.48	84.67	74.78	132.57
(b) Diluted (₹)	45.52	39.15	39.48	84.67	74.78	132.57

Unaudited Statement of Consolidated Assets and Liabilities as at 30 September 2021

(₹ in Million)

Particulars	As at 30 September 2021 (Unaudited)	As at 31 March 2021 (Audited)
I. ASSETS		
1 Non-current assets		
(a) Property, plant and equipment	23,482.2	22,339.3
(b) Capital work-in-progress	3,180.9	3,932.8
(c) Goodwill	3,976.7	3,953.9
(d) Other Intangible assets	1,706.0	1,636.6
(e) Financial Assets		
(i) Investments	1,699.0	1,539.5
(ii) Loans	80.2	80.2
(iii) Others financial assets	2,490.2	607.9
(f) Deferred tax assets (net)	12,355.0	11,079.1
(g) Non-current tax assets (net)	191.4	171.1
(h) Other non-current assets	769.4	564.0
Total Non-current assets	49,931.0	45,904.4
2 Current assets		
(a) Inventories	25,277.3	23,124.4
(b) Financial Assets		
(i) Investments	1,752.7	1,788.3
(ii) Trade receivables	18,017.5	16,072.1
(iii) Cash and cash equivalents	3,336.0	1,742.2
(iv) Bank balances other than (iii) above	20,611.0	18,162.3
(v) Loans	223.8	187.3
(vi) Others financial assets	2,227.6	2,606.0
(c) Other current assets	5,368.6	5,550.1
(d) Non-current assets held for sale	48.2	55.5
Total Current assets	76,862.7	69,288.2
TOTAL ASSETS	126,793.7	115,192.6
II. EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	239.1	239.1
(b) Other Equity	83,099.5	73,528.2
Equity attributable to owners of the Company	83,338.6	73,767.3
(c) Non-controlling interest	1,997.5	1,812.8
Total Equity	85,336.1	75,580.1
2 Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	87.2	279.3
(ia) Lease liabilities	791.4	697.1
(b) Provisions	3,361.5	2,507.3
(c) Other non-current liabilities	85.0	88.3
Total Non-Current liabilities	4,325.1	3,572.0
3 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	17,001.8	16,727.9
(ia) Lease liabilities	223.5	215.5
(ii) Trade payables		
Dues of Micro and Small Enterprises	526.7	1,189.6
Dues of Creditors other than Micro and Small Enterprises	9,013.1	9,504.5
(iii) Other financial liabilities	5,579.2	4,653.9
(b) Other current liabilities	1,467.1	1,193.4
(c) Provisions	2,626.8	2,366.4
(d) Current tax Liabilities (Net)	694.3	189.3
Total Current liabilities	37,132.5	36,040.5
TOTAL EQUITY AND LIABILITIES	126,793.7	115,192.6

Unaudited Statement of Consolidated Cash flow for the Six months ended 30 September 2021

(₹ in million)

Particulars	For six months ended 30 September 2021 (Unaudited)	For six months ended 30 September 2020 (Unaudited)
A Cash Flow from Operating Activities:		
Profit before Tax	11,376.6	10,405.0
<u>Adjustments for:</u>		
Depreciation and amortisation expense	1,433.6	1,370.7
Liabilities no longer required , written back	(67.7)	-
Profit on sale of investments	(22.8)	(14.6)
Unrealised gain on fair valuation of investments (net)	(38.7)	(65.8)
Profit on sale of property plant and equipment (net)	(4.9)	4.0
Employee stock compensation expenses	-	0.6
Unrealised foreign currency (gain) / loss on revaluation (net)	(48.1)	206.4
Dividend Income	(0.2)	(0.1)
Recovery of bad debts	-	(114.9)
Interest Income	(547.1)	(407.5)
Interest expenses	248.3	351.4
Allowances for doubtful debts	26.8	52.2
Rent income	-	(4.2)
Subtotal of Adjustments	979.2	1,378.2
Operating profit before working capital changes	12,355.8	11,783.2
Adjustments for changes in working capital:		
Increase in trade receivables	(1,795.0)	(114.7)
(Increase) / Decrease in loans, other financial assets and other assets	744.3	(280.3)
Increase in inventories	(2,167.7)	(1,698.0)
Increase / (Decrease) in trade payable, other financial liabilities and other liabilities	160.3	(1,038.3)
Increase in provisions	783.8	625.2
Subtotal of adjustments	(2,274.3)	(2,506.1)
Cash generated from operations	10,081.5	9,277.1
Less: Income taxes paid (net of refund)	(1,760.3)	(1,520.2)
Net Cash generated from operating activities	8,321.2	7,756.9
B Cash Flow from Investing Activities:		
Purchases of property, plant and equipment	(1,813.9)	(676.7)
Sale of property, plant and equipment	19.0	5.9
(Purchase of) / Proceeds from sale of investments (net)	(58.6)	3.4
Investment made in bank deposits having maturity of more than 3 months (net)	(4,306.9)	(4,994.2)
Dividend received	0.2	0.1
Interest received	389.7	318.3
Rent received	-	4.2
Net cash used in investing activities	(5,770.5)	(5,339.0)
C Cash Flow from Financing Activities:		
Repayment of non-current borrowings (net)	(192.8)	(262.5)
(Repayment of) / Proceeds from current borrowings (net)	225.8	(1,437.3)
Dividends paid	(632.1)	(358.7)
Repayment of lease liabilities (net)	(156.5)	(101.9)
Interest and bank charges paid	(208.5)	(296.8)
Net cash used in financing activities	(964.1)	(2,457.2)
D Net (decrease)/increase in Cash and Cash Equivalents (A+B+C)	1,586.6	(39.3)
E Cash & Cash Equivalents as at the beginning of the year	1,742.2	1,759.4
Add/Less: Effect of exchange difference on foreign currency cash and cash equivalents	7.2	5.5
F Cash & Cash Equivalents as at the end of the period (D+E)	3,336.0	1,725.6

Notes:

- The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - "Statement of Cash Flows".

Notes to the Consolidated Financial results:

- 1 The above unaudited consolidated financial results of the Company were reviewed and recommended by the Audit Committee on 11 November 2021 and subsequently approved by the Board of Directors at its meeting held on 12 November 2021. The auditors have issued an unmodified report on the financial results for the quarter and six months ended 30 September 2021.
- 2 The Group has considered internal and external information while assessing recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Group expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Group has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Group will continue to closely monitor any material changes to future economic conditions.
- 3 Pursuant to the Board of Directors approval at its meeting held on 25 May 2021 on the proposed plan for restructuring of the USA business operations by bringing both the subsidiaries namely, S & B Pharma Inc, USA ("S & B") and The PharmaNetwork LLC, USA ("TPNC") under a single umbrella by removing intermediary holding company S & B Holdings BV, Netherlands ("S & B BV"), the Company on 04 October 2021 has consummated the transaction whereby TPNC acquired 100% shares of S&B from the Company in exchange of TPNC's shares.
- 4 During the quarter ended 30 September 2021, the Company paid a final dividend of ₹ 5 (Rupees five only) per equity share (250% on the face value of ₹ 2 each) for the financial year 2020-21.
- 5 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.
- 6 Previous period figures have been regrouped/reclassified wherever required, to make them comparable with the figures for the current period.

Place: Mumbai
Date: 12 November 2021

By Order of the Board
For Alkem Laboratories Limited
Basudeo Narayan Singh
Digitally signed by Basudeo Narayan Singh
Date: 2021.11.12 11:33:59 +05'30'
B.N. Singh
Executive Chairman
DIN: 00760310

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited review report on unaudited quarterly standalone financial results and standalone year-to-date results of Alkem Laboratories Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Alkem Laboratories Limited (“the Company”) for the quarter ended and year to date results for the period from 1 April 2021 to 30 September 2021 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants

Firm's Registration No: 101248W/W-100022

BALAJIRAO
VENKATESWAR
RAO POTHANA

Digitally signed by
BALAJIRAO
VENKATESWARRAO
POTHANA
Date: 2021.11.12 12:14:29
+05'30'

Balajirao Pothana
Partner

Membership No: 122632

UDIN No: 21122632AAAACY3363

Mumbai
12 November 2021

Registered Office:

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Unaudited Statement of Standalone Financial Results for the Quarter and Six months ended 30 September 2021

(₹ in Million except per share data)

Particulars	Quarter ended			Six months ended		Year ended
	30.09.2021 Unaudited	30.06.2021 Unaudited	30.09.2020 Unaudited	30.09.2021 Unaudited	30.09.2020 Unaudited	31.03.2021 Audited
1 Income						
(a) Revenue from Operations	23,639.9	22,786.7	19,841.0	46,426.6	35,234.6	72,196.8
(b) Other Income	432.1	392.1	248.4	824.2	687.8	1,900.1
Total Income	24,072.0	23,178.8	20,089.4	47,250.8	35,922.4	74,096.9
2 Expenses						
(a) Cost of materials consumed	6,967.5	6,538.1	3,915.4	13,505.6	8,579.4	20,465.2
(b) Purchases of stock-in-trade	2,987.2	2,629.7	2,573.8	5,616.9	4,675.6	9,197.9
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(670.5)	(41.6)	1,095.6	(712.1)	(738.5)	(3,012.9)
(d) Employee benefits expense	3,615.0	4,022.3	2,951.3	7,637.3	5,795.6	11,587.2
(e) Finance costs	85.0	90.6	147.6	175.6	268.0	429.3
(f) Depreciation and amortisation expense	538.2	517.2	516.2	1,055.4	994.7	1,989.3
(g) Other expenses	4,862.3	4,132.5	3,362.2	8,994.8	6,029.0	14,470.1
Total Expenses	18,384.7	17,888.8	14,562.1	36,273.5	25,603.8	55,126.1
3 Profit before exceptional items and tax (1) - (2)	5,687.3	5,290.0	5,527.3	10,977.3	10,318.6	18,970.8
4 Exceptional items (Refer Note 4)	-	-	-	-	-	(127.8)
5 Profit before tax (3) + (4)	5,687.3	5,290.0	5,527.3	10,977.3	10,318.6	18,843.0
6 Tax expense / (credit)						
(a) Current tax	989.6	916.2	974.9	1,905.8	1,808.2	3,318.3
(b) Deferred tax	(882.4)	(318.9)	(399.6)	(1,201.3)	(703.2)	(1,326.1)
Total Tax Expense (a + b)	107.2	597.3	575.3	704.5	1,105.0	1,992.2
7 Profit for the period after tax (5 - 6)	5,580.1	4,692.7	4,952.0	10,272.8	9,213.6	16,850.8
8 Other Comprehensive Income (net of tax)						
(a) (i) Items that will not be reclassified to profit or loss	(15.9)	(16.0)	2.4	(31.9)	(7.4)	(76.7)
(ii) Income tax relating to items that will not be reclassified to profit or loss	5.6	5.6	(0.8)	11.2	2.6	26.8
(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other Comprehensive Income (net of tax)	(10.3)	(10.4)	1.6	(20.7)	(4.8)	(49.9)
9 Total Comprehensive Income for the period (7) + (8)	5,569.8	4,682.3	4,953.6	10,252.1	9,208.8	16,800.9
10 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1	239.1	239.1
11 Other Equity						76,018.4
12 Earnings Per Share (not annualised for the periods)						
(a) Basic (₹)	46.67	39.25	41.42	85.92	77.06	140.93
(b) Diluted (₹)	46.67	39.25	41.42	85.92	77.06	140.93

Unaudited Statement of Standalone Assets and Liabilities as at 30 September 2021

(₹ in Million)

Particulars	As at 30 September 2021 (Unaudited)	As at 31 March 2021 (Audited)
I. ASSETS		
1 Non-current assets		
(a) Property, plant and equipment	17,812.2	16,486.0
(b) Capital work-in-progress	2,044.6	3,232.6
(c) Intangible assets	1,174.2	1,097.6
(d) Investment in subsidiaries	22,755.3	18,770.4
(e) Financial Assets		
(i) Investments	1,086.2	1,131.7
(ii) Loans	173.0	333.2
(iii) Others financial assets	2,135.7	221.3
(f) Deferred tax assets (net)	10,756.9	9,544.3
(g) Non current tax assets (net)	74.2	70.2
(h) Other non-current assets	609.2	524.6
Total Non-current assets	58,621.5	51,411.9
2 Current assets		
(a) Inventories	15,857.1	15,132.6
(b) Financial Assets		
(i) Investments	1,579.2	1,621.7
(ii) Trade receivables	19,043.7	15,565.5
(iii) Cash and cash equivalents	873.1	152.2
(iv) Bank balances other than (iii) above	19,122.8	16,581.4
(v) Loans	155.8	116.1
(vi) Others financial assets	2,013.6	2,377.0
(c) Other current assets	4,331.2	4,713.4
(d) Non-current assets held for sale	48.2	55.5
Total Current assets	63,024.7	56,315.4
TOTAL ASSETS	121,646.2	107,727.3
II. EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	239.1	239.1
(b) Other Equity	85,672.6	76,018.4
Total Equity	85,911.7	76,257.5
2 Non-current liabilities		
(a) Financial Liabilities		
(i) Lease liabilities	486.4	396.9
(b) Provisions	2,613.4	1,904.2
(c) Other non-current liabilities	67.3	69.3
Total Non-Current liabilities	3,167.1	2,370.4
3 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	16,312.3	13,328.4
(ia) Lease liabilities	113.7	109.8
(ii) Trade payables		
Dues of Micro and Small Enterprises	311.6	1,044.7
Dues of creditors other than Micro and Small Enterprises	8,155.7	8,484.5
(iii) Other financial liabilities	4,242.7	3,226.9
(b) Other current liabilities	936.1	918.5
(c) Provisions	1,944.0	1,936.5
(d) Current tax Liabilities (Net)	551.3	50.1
Total Current liabilities	32,567.4	29,099.4
TOTAL EQUITY AND LIABILITIES	121,646.2	107,727.3

Unaudited Statement of Standalone Cash Flow for the Six months ended 30 September 2021

(₹ in million)

Particulars	For six months ended 30 September 2021 (Unaudited)	For six months ended 30 September 2020 (Unaudited)
A. <u>Cash Flow from Operating Activities:</u>		
Profit before tax	10,977.3	10,318.6
<u>Adjustments for:</u>		
Depreciation and amortisation	1,055.4	994.7
Unrealised (gain) / loss on fair valuation of investments (net)	(38.7)	(53.3)
Profit on sale of investments (net)	(19.1)	(14.3)
Loss / (profit) on sale of property plant and equipment (net)	(4.9)	0.1
Dividend income	(35.7)	-
Interest income	(491.9)	(349.3)
Interest expenses	175.6	268.0
Allowances for doubtful debts	4.1	32.8
Liabilities no longer required , written back	(67.7)	-
Recovery of bad debts	-	(114.9)
Unrealised foreign currency (gain) / loss on revaluation (net)	(93.5)	202.8
Rent income	-	(11.3)
Subtotal of Adjustments	483.6	955.3
Operating profit before working capital changes	11,460.9	11,273.9
Adjustments for changes in working capital:		
Increase in trade receivables	(3,306.6)	(33.3)
(Increase) / Decrease in loans, other financial assets and other assets	968.4	(173.1)
Increase in inventories	(724.5)	(1,486.1)
Increase in trade payable, other financial liabilities and other liabilities	36.2	(746.4)
Increase in provisions	684.8	359.9
Subtotal of Adjustments	(2,341.7)	(2,079.0)
Cash generated from operations	9,119.2	9,194.9
Less: Income taxes paid (net of refund)	(1,408.8)	(1,126.8)
Net cash generated from operating activities	7,710.4	8,068.1
B <u>Cash Flow from Investing Activities:</u>		
Purchases of property, plant and equipment	(1,168.3)	(512.9)
Sale of property, plant and equipment	18.0	3.1
Proceeds from sale of investments (net)	145.9	32.2
Investments in subsidiaries	(3,985.0)	(1,496.2)
Investment made in bank deposits having maturity of more than 3 months (net)	(4,444.1)	(4,991.3)
Dividend received	35.7	-
Interest received	334.4	260.0
Rent received	-	11.3
Net Cash used in investing activities	(9,063.4)	(6,693.8)
C <u>Cash Flow from Financing Activities:</u>		
(Repayment of) / Proceeds from current borrowings (net)	2,906.6	(695.4)
Repayment of lease liabilities (net)	(80.0)	(51.2)
Dividends paid	(597.8)	(358.7)
Interest paid	(154.9)	(215.7)
Net cash (used in)/generated from financing activities	2,073.9	(1,321.0)
D Net (decrease)/increase in cash and cash equivalents (A+B+C)	720.9	53.3
E Cash and cash equivalents as at beginning of the year	152.2	206.9
F Cash and cash equivalents as at end of the period (D+E)	873.1	260.2

Notes:

- The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - "Statement of Cash Flows"

Notes to the Standalone Financial results:

- 1 The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 11 November 2021 and subsequently approved by the Board of Directors at its meeting held on 12 November 2021. The auditors have issued an unmodified report on the financial results for the quarter and six months ended 30 September 2021.
- 2 The Company has considered internal and external information while assessing recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Company expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Company has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- 3 Pursuant to the Board of Directors approval at its meeting held on 25 May 2021 on the proposed plan for restructuring of the USA business operations by bringing both the subsidiaries namely, S & B Pharma Inc, USA ("S & B") and The PharmaNetwork LLC, USA ("TPNC") under a single umbrella by removing intermediary holding company S & B Holdings BV, Netherlands ("S & B BV"), the Company on 04 October 2021 has consummated the transaction whereby TPNC acquired 100% shares of S&B from the Company in exchange of TPNC's shares.
- 4 The Company has made an assessment of the recoverable value of investment in its subsidiaries taking into account the decline in operational performance, changes in the outlook of future profitability, weaker market conditions, among other potential indicators. Accordingly, during the year ended 31 March 2021, an impairment loss of Rs.127.8 Million was recognised towards investment in Alkem Laboratories Corporation, Philippines, a wholly owned subsidiary of the Company in accordance with IND AS 36 'Impairment of assets' and the same has been disclosed as an 'Exceptional item'.
- 5 During the quarter ended 30 September 2021, the Company paid a final dividend of ₹ 5 (Rupees five only) per equity share (250% on the face value of ₹ 2 each) for the financial year 2020-21.
- 6 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.
- 7 Previous period figures have been regrouped/reclassified wherever required, to make them comparable with the figures for the current period.

Place: Mumbai
Date: 12 November 2021

By Order of the Board
For Alkem Laboratories Limited

Basudeo
Narayan
Singh

Digitally signed by
Basudeo Narayan
Singh
Date: 2021.11.12
11:35:02 +05'30'

B.N. Singh
Executive Chairman
DIN: 00760310



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Press Release

Alkem reports Q2FY22 and H1FY22 results

Mumbai, November 12, 2021: Alkem Laboratories Ltd. (Alkem) today announced its standalone and consolidated financial results for the second quarter and six months ended September 30, 2021. These results were taken on record by the Board of Directors at its meeting held in Mumbai today.

Key highlights of Q2FY22 financial performance

- Total Revenue from Operations was ₹ 28,000 million, year-on-year growth of 18.5%
 - India sales were ₹ 19,605 million, year-on-year growth of 25.9%
 - International sales were ₹ 8,052 million, year-on-year growth of 3.4%
- Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 6,244 million, resulting in EBITDA margin of 22.3% vs. 25.4% in Q2FY21. EBITDA grew by 4.0% YoY
- R&D expenses for the quarter was ₹ 1,407 million, or 5.0% of total revenue from operations compared to ₹ 1,393 million in Q2FY21 at 5.9% of total revenue from operations
- Profit before tax (PBT) was ₹ 5,815 million, a growth of 6.2% compared to Q2FY21
- Net Profit (after Minority Interest) was ₹ 5,443 million, year-on-year growth of 15.3%

Key highlights of H1FY22 financial performance

- Total Revenue from Operations was ₹ 55,314 million, year-on-year growth of 27.0%
 - India sales were ₹ 38,702 million, year-on-year growth of 42.7%
 - International sales were ₹ 15,955 million, year-on-year growth of 2.0%
- Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 12,172 million, resulting in EBITDA margin of 22.0% vs. 25.8% in H1FY21. EBITDA grew by 8.5% YoY
- R&D expenses for H1FY22 was ₹ 2,590 million, or 4.7% of total revenue from operations compared to ₹ 2,579 million in H1FY21 at 5.9% of total revenue from operations
- Profit before tax (PBT) was ₹ 11,377 million, a growth of 9.3% compared to H1FY21
- Net Profit (after Minority Interest) was ₹ 10,124 million, year-on-year growth of 13.2%

Commenting on the results, Sandeep Singh, Managing Director, Alkem said, *“First six months of the financial year has been a very healthy period for the Company’s India business with over 40% YoY growth mainly driven by the acute therapies. Even in chronic therapies and trade generic business, the Company continues to grow ahead of the market. In the US business, new product launches have helped to offset significant pricing pressure in the base business. Our continuous efforts towards cost optimization and driving process efficiencies are also showing good results with improvement in profitability.”*



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Operational Highlights

Domestic Business

In Q2FY22, the Company's India sales grew by 25.9% YoY, recording sales of ₹ 19,605 million as compared to ₹ 15,574 million in Q2FY21. For H1FY22, the Company's India sales was ₹ 38,702 million compared to ₹ 27,124 million in H1FY21 – growth of 42.7% YoY.

As per secondary sales data by IQVIA for the quarter ended September 30, 2021, the Company grew ahead of Indian Pharmaceutical Market (IPM) with growth of 25.1% YoY compared to IPM growth of 15.4% YoY. Even for H1FY22, the Company outperformed the IPM with growth of 40.4% YoY compared to IPM growth of 26.4% YoY. This outperformance was mainly driven by acute therapies like anti-infectives, vitamins/minerals/nutrients and pain management which witnessed a good volume growth during the first six month of the financial year. Company's chronic therapies of neuro / CNS, anti-diabetes, cardiac and derma also grew faster than the segment growth rate, thereby gaining market share and improving their market rankings. The Company continues to feature amongst the top five companies in the Indian pharmaceutical market. The Company has 16 brands which feature amongst the top 300 brands in IPM and have 13 brands with annual sales of over ₹ 1bn. Company's trade generic business also delivered healthy growth during Q2FY22 and H1FY22.

The performance highlights of the key therapeutic segments in Q2FY22 and H1FY22 are as shown in the table below:

Key Therapy segment	Q2FY22				H1FY22			
	Alkem Rank	YoY change in Rank*	YoY growth (Alkem)	YoY growth (IPM)	Alkem Rank	YoY change in Rank*	YoY growth (Alkem)	YoY growth (IPM)
Anti-infectives	1	Unchanged	32.8%	30.6%	1	Unchanged	54.9%	55.5%
Gastro Intestinal	3	Unchanged	11.6%	14.6%	3	Unchanged	21.3%	23.4%
Pain / Analgesics	3	Unchanged	22.2%	21.9%	4	-1	31.5%	28.3%
VMN**	2	+2	16.0%	8.2%	2	+2	45.2%	25.5%
Neuro / CNS	8	+2	38.2%	12.3%	8	+3	38.6%	12.9%
Derma	14	+3	40.8%	9.4%	19	-1	45.0%	16.0%
Cardiac	27	-1	10.0%	6.9%	27	-1	17.2%	13.0%
Anti-Diabetic	18	+2	27.8%	5.7%	19	+2	30.9%	8.5%
Total	4	+1	25.1%	15.4%	5	Unchanged	40.4%	26.4%

*Positive change in rank reflects improvement over same period previous year

**VMN – Vitamins / Minerals / Nutrients

Source: IQVIA Data

International Business

In Q2FY22, the Company's International sales grew by 3.4% YoY, recording sales of ₹ 8,052 million as compared to ₹ 7,790 million in Q2FY21. For H1FY22, the Company's International sales grew by 2.0% to ₹ 15,955 million compared to ₹ 15,643 million in H1FY21.



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

- **US sales** for the quarter was ₹ 6,097 million compared to ₹ 6,528 million in Q2FY21, recording a year-on-year decline of 2.6%. For H1FY22, US sales was ₹ 12,140 million, compared to ₹ 12,921 million in H1FY21 - a year-on-year decline of 6.0% YoY.
- **Other International Markets sales** for the quarter was ₹ 1,954 million compared to ₹ 1,532 million in Q2FY21, recording a year-on-year growth of 27.5%. For H1FY22, Other International Markets sales was ₹ 3,815 million compared to ₹ 2,722 million in H1FY21 - a year-on-year growth of 40.2% YoY.

R&D Investments

During the quarter, the Company filed 6 abbreviated new drug applications (ANDAs) with the US FDA and received 7 approvals (including 2 tentative approvals). For H1FY22, the Company filed 8 ANDAs with the US FDA and received 12 approvals (including 2 tentative approvals).

As on September 30, 2021, the Company has filed a total of 157 ANDAs and 2 new drug applications (NDA) with the US FDA. Of these, it has received approvals for 116 ANDAs (including 14 tentative approvals) and 2 NDAs.

Update on US FDA Inspections

Facility	Capability	Last inspection	Status post last inspection
St. Louis (US)	Formulations	June 2021	Received 2 observations. The Company has already submitted a detailed response to the US FDA on the corrective and preventive actions it is taking to address them
Baddi (India)	Formulations	February 2020	EIR# received in March 2020, thereby successfully closing the inspection
Daman (India)	Formulations	August 2019	EIR# received in October 2019, thereby successfully closing the inspection
California (US)	APIs	August 2018	Successfully closed without any observations. EIR received in October 2018
Ankleshwar (India)	APIs	December 2016	EIR# received in March 2017, thereby successfully closing the inspection
Mandva (India)	APIs	September 2015	EIR# received in March 2016, thereby successfully closing the inspection

EIR – Establishment Inspection Report

The US FDA had also conducted a remote and virtual Bio-Analytical inspection of the Company's Bioequivalence Center located at Taloja, Maharashtra from 26 to 28 July, 2021. At the end of the inspection, no Form 483 was issued.



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Q2FY22 and H1FY22 Conference Call at 8:00pm IST, November 12, 2021

Alkem will organize a conference call for investors and analysts on Friday, November 12, 2021 from 8:00 pm to 9:00 pm IST to discuss its Q2FY22 and H1FY22 financial results.

Alkem will be represented on the call by Mr. Sandeep Singh, Managing Director and the senior management team.

Motilal Oswal Securities Ltd. will host the call.

Details of the conference call are as under:

Time: 8:00 pm IST (GMT + 5:30) on Friday, November 12, 2021

Dial in Details:

India : +91 22 6280 1149 / +91 22 7115 8050

International Toll Free

USA : 1 866 746 2133
UK : 0 808 101 1573
Singapore : 800 101 2045
Hong Kong : 800 964 448

Express Join with Diamond Pass

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=5628564&linkSecurityString=1603896b58>

You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com

About Alkem Laboratories Ltd.

Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA March 2021). The Company also has presence in more than 40 international markets, with the United States being its key focus market. For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com

For further information or queries, please contact

Gagan Borana

Investor Relations

Tel: +91 22 3982 9960 / Mobile: +91 98190 56333

E-mail: gagan.borana@alkem.com



ALKEM LABORATORIES LIMITED

ALKEM

अल्केम

Investor Presentation Q2FY22
November 12, 2021



Safe Harbor Statement

This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.

Key Highlights of Q2FY22 and H1FY22

Strong growth in the India business and new product launches in US driving the performance

- **Revenue from Operations** grew by 18.5% YoY during the quarter, with EBITDA margin of 22.3% and Net Profit growth of 15.3% YoY
- **India Business:** Company's secondary sales in Q2FY22 registered growth of 25.1% YoY compared to IPM growth of 15.4% YoY (Source: IQVIA data)
 - During the quarter, the Company launched Pulmocare division to build its presence in the respiratory therapy
 - Strong volume led growth in the acute therapies
 - Faster than market growth in chronic therapies
 - Trade Generic business continues to deliver robust growth
- **US Business** – New product launches helped offset significant pricing pressure in the base business
- **R&D** expenses in the quarter was ₹ 1.4 billion at 5.0% of revenue from operations
 - The Company filed 6 ANDAs with the US FDA and received 7 approvals (including 2 tentative approvals) in Q2FY22
- In Q2FY22, Company's Bioequivalence centre **successfully closed the US FDA inspection** without any observations
- **Healthy Balance Sheet** with net cash of ₹ 11.6 billion as on September 30, 2021


Key Financial Highlights – Q2FY22 (Consolidated)

All figures in ₹ mn


Revenue from Operations



India sales



International sales




Key Financial Highlights – Q2FY22 (Consolidated)




All figures in ₹ mn


Gross Profit and Gross Margin




EBITDA and EBITDA Margin



PBT (before Minority Interest)



PAT (after Minority Interest)



Key Financial Highlights – H1FY22 (Consolidated)



All figures in ₹ mn


Particulars (₹ mn)	H1FY22	H1FY21	YoY growth
Revenue from Operations	55,314	43,548	27.0%
Gross Profit	33,791	26,870	25.8%
Gross Profit margin	61.1%	61.7%	
EBITDA	12,172	11,222	8.5%
EBITDA margin	22.0%	25.8%	
PBT	11,377	10,405	9.3%
PBT margin	20.6%	23.9%	
PAT (After Minority Interest)	10,124	8,941	13.2%
PAT margin	18.3%	20.5%	
EPS (₹ / share)	84.67	74.78	13.2%

India Business


India Business: Q2FY22 Sales of ₹ 19,605 million (25.9% YoY growth)

- India sales contributed 70.9% to total sales in Q2FY22
- In H1FY22, the Company's secondary sales grew by 40.4% YoY compared to IPM growth of 26.4% YoY (Source: IQVIA data)
- Growth was mainly led by acute therapies like anti-infectives, vitamins / minerals / nutrients, gastrointestinal and pain management segment
- The Company also outperformed in the chronic therapies like neuro / CNS, cardiac, anti-diabetes and derma during the quarter
- Company's Trade Generic business delivered a robust growth during the quarter

Q2FY22 – India Sales (₹ mn)





H1FY22 – India Sales (₹ mn)



Secondary Sales Performance

Robust growth across all the major therapeutic segments in Q2FY22



Source: IQVIA data ¹ Domestic formulations sales; ² For 3 months ended September 30, 2021

US Business


US Business: Q2FY22 Sales of ₹ 6,097 million (YoY decline of 2.6%)

- US sales contributed 22.0% to total sales in Q2FY22
- During the quarter, the US business registered sequential growth of 0.9% over Q1FY22. Significant pricing pressure on the base business was offset by new product launches
- In H1FY22, the Company filed 8 ANDAs with the US FDA and received 12 approvals (including 2 tentative approvals)
- As on September 30, 2021, the Company has filed a total of 159 ANDAs (including 2 NDAs) with the US FDA and has received 118 approvals (including 14 tentative approvals and 2 NDAs)

Q2FY22 – US Sales (₹ mn)



H1FY22 – US Sales (₹ mn)



US Business

Update on US FDA inspections

Manufacturing Facility	Capability	Last inspection	Status post last inspection
St. Louis (US)	Formulations	June 2021	Received 2 observations. Already sent a detail response to the US FDA on the corrective and preventive actions being taken
Baddi (India)	Formulations	February 2020	EIR# received in March 2020
Daman (India)	Formulations	August 2019	EIR# received in October 2019
California (US)	APIs	August 2018	EIR# received in October 2018
Ankleshwar (India)	APIs	December 2016	EIR# received in March 2017
Mandva (India)	APIs	September 2015	EIR# received in March 2016

EIR – Establishment Inspection Report indicating successful closure of inspection


The US FDA had also conducted a remote and virtual Bio-Analytical inspection of the Company's Bioequivalence Center located at Taloja, Maharashtra from 26th to 28th July, 2021. At the end of the inspection, no Form 483 was issued.

Other International Business


Other International Business: Q2FY22 Sales of ₹ 1,954 million (27.5% YoY growth)

- Other International Market sales contributed 7.1% to total sales in Q2FY22
- The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS
- Key markets like Australia, Chile, Philippines and UK registered healthy growth during H1FY22

**Q2FY22 – Other International Sales
(₹ mn)**




**H1FY22 – Other International Sales
(₹ mn)**



Latest Shareholding Pattern

Shareholding pattern as on September 30, 2021



Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks

Non-Institution – Public, Other Bodies Corporates, Clearing Members, Non Resident Indians, Hindu Undivided Family and Trusts

Thank You

For further information or queries, please contact

Gagan Borana

Investor Relations

Tel: +91 22 3982 9960

E-mail: gagan.borana@alkem.com